



Notification 6427

Implementation Date

10/5/2023

Category

HCPCS - Drugs & Biologicals

Topic

Louisiana Medicaid – Frequency limitation for vedolizumab, 1 mg

What is changing?

We limit reimbursement of charges for vedolizumab, 1 mg, to claims that meet the following criteria:

- Second dose must be at least 2 weeks after initial dose
- Subsequent doses must be at least 4 weeks after the second dose and at least 8 weeks thereafter

Language

English

Impacted Products

- Medicaid – Louisiana

Why is Humana making this change?

According to the FDA-approved package insert and prescribing information and pharmaceutical compendia, vedolizumab, 1 mg, is limited to the frequencies listed above.